Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Leases (2019 - 2025)

Syndax Pharmaceuticals has reported Current Leases over the past 7 years, most recently at $470000.0 for Q4 2025.

  • Quarterly results put Current Leases at $470000.0 for Q4 2025, changed 0.21% from a year ago — trailing twelve months through Dec 2025 was $470000.0 (changed 0.21% YoY), and the annual figure for FY2025 was $470000.0, changed 0.21%.
  • Current Leases for Q4 2025 was $470000.0 at Syndax Pharmaceuticals, up from $329000.0 in the prior quarter.
  • Over the last five years, Current Leases for SNDX hit a ceiling of $1.0 million in Q1 2024 and a floor of $299000.0 in Q2 2022.
  • Median Current Leases over the past 5 years was $462000.0 (2023), compared with a mean of $571750.0.
  • Biggest five-year swings in Current Leases: soared 220.07% in 2023 and later tumbled 64.93% in 2025.
  • Syndax Pharmaceuticals' Current Leases stood at $361000.0 in 2021, then rose by 20.22% to $434000.0 in 2022, then soared by 138.48% to $1.0 million in 2023, then plummeted by 54.49% to $471000.0 in 2024, then dropped by 0.21% to $470000.0 in 2025.
  • The last three reported values for Current Leases were $470000.0 (Q4 2025), $329000.0 (Q3 2025), and $344000.0 (Q2 2025) per Business Quant data.